I. M. Nazaryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
I. M. Nazaryan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ruzanna G. Paronikyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A. L. Mnjoyan, 0014, Armenia
2 shared publications A. D. Harutyunyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
1 shared publication- Anahit E. Pogosyan
Scientific and Technological Center of Organic and Pharmaceutical Chemistry of the National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
1 shared publication - Ervand G. Paronikyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of Armenia, Yerevan, Armenia
1 shared publication - Hrachik V. Gasparyan
Scientific and Technological Center of Organic and Pharmaceutical Chemistry of the National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
1 shared publication K. A. Gevorkyan
Scientific Technological Center of Organic and Pharmaceutical Chemistry, National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia
1 shared publication
Latest Publications
- 1 May 2025
- Published by Pleiades Publishing Ltd in Russian Journal of Organic Chemistry
- Vol. 61 (5) , 864-871
Synthesis and Neurotropic Activity of Cyclic and Spirocyclic Derivatives of 1,3-Diazadamantane
Cyclic and spirocyclic 1,3-diazaadamantane derivatives were synthesized by the condensation of substituted 3,7-diazabicyclo[3.3.1]nonanes with cyclic and heterocyclic aldehydes and ketones. Screening for neurotropic activity showed that spirocyclic 1,3-diazaadamantanes exhibit a higher potency than their cyclic analogs, with activity levels of 40–60 against 20–40%, respectively.
- 1 May 2025
- Published by Pleiades Publishing Ltd in Russian Journal of Organic Chemistry
- Vol. 61 (5) , 864-871
Synthesis and Neurotropic Activity of Cyclic and Spirocyclic Derivatives of 1,3-Diazadamantane
Cyclic and spirocyclic 1,3-diazaadamantane derivatives were synthesized by the condensation of substituted 3,7-diazabicyclo[3.3.1]nonanes with cyclic and heterocyclic aldehydes and ketones. Screening for neurotropic activity showed that spirocyclic 1,3-diazaadamantanes exhibit a higher potency than their cyclic analogs, with activity levels of 40–60 against 20–40%, respectively.
- 1 January 2021
- Published by FSBSI Research Institute of Human Morphology in CLINICAL AND EXPERIMENTAL MORPHOLOGY
- Vol. 10 (4)
Pathological investigation of neuroprotective activity of new derivatives of fused pyrazolyl-thienopyridines in Corazol-induced seizures
Introduction. Seizures provoke several morphological alterations in the brain structures. These alterations are primarily located in the hippocampal CA1 region and the entorhinal cortex. Recurrent seizures are common in patients with epilepsy. Therapeutic options for this disease are very limited and most of them are aimed at relieving symptoms. In most cases, to treat epilepsy, anti-seizure drugs are used. Nevertheless, one-third of affected individuals have resistance to them. Thus, the study of new effective agents that can prevent epileptogenesis is still an ongoing challenge. In this work, we aimed to study the neuroprotective activity of several new derivatives of tricyclic pyrazolyl substituted thieno[2,3-c]isoquinolins (SHD-89 and SHD-91) and pyrano[4,3-d]thieno[2,3-b]pyridines (SHD-78 and SHD-85) as potential anti-seizure drugs. Materials and methods. The study was performed on mice (n=60). The action of compounds SHD-78, SHD-85, SHD-89, and SHD-91 was tested in seizures with and without Corazol administration. Histopathological examinations were performed in the hippocampus and the entorhinal cortex in different experimental groups. Results. The study showed that under the action of SHD-89 and SHD-78, there was a reduction in the number of neurons and activation of glial cells in examined regions of the brain. SHD-91 caused severe neurode-generative effects with changes in the brain structure. In contrast, under the action of SHD-85, the number of neurons was higher and with lower activation of glial cells. Conclusion. Studies showed that among the tested compounds SHD-85 possessed moderate neuroprotective activity and reduced gliosis and neuronal loss induced by Corazol. Keywords: anti-seizure drugs, pyrazolylthienopyridines, hippocampus, entorhinal cortex, histopathological examination
- 1 January 2021
- Published by FSBSI Research Institute of Human Morphology in CLINICAL AND EXPERIMENTAL MORPHOLOGY
- Vol. 10 (4)
Pathological investigation of neuroprotective activity of new derivatives of fused pyrazolyl-thienopyridines in Corazol-induced seizures
Introduction. Seizures provoke several morphological alterations in the brain structures. These alterations are primarily located in the hippocampal CA1 region and the entorhinal cortex. Recurrent seizures are common in patients with epilepsy. Therapeutic options for this disease are very limited and most of them are aimed at relieving symptoms. In most cases, to treat epilepsy, anti-seizure drugs are used. Nevertheless, one-third of affected individuals have resistance to them. Thus, the study of new effective agents that can prevent epileptogenesis is still an ongoing challenge. In this work, we aimed to study the neuroprotective activity of several new derivatives of tricyclic pyrazolyl substituted thieno[2,3-c]isoquinolins (SHD-89 and SHD-91) and pyrano[4,3-d]thieno[2,3-b]pyridines (SHD-78 and SHD-85) as potential anti-seizure drugs. Materials and methods. The study was performed on mice (n=60). The action of compounds SHD-78, SHD-85, SHD-89, and SHD-91 was tested in seizures with and without Corazol administration. Histopathological examinations were performed in the hippocampus and the entorhinal cortex in different experimental groups. Results. The study showed that under the action of SHD-89 and SHD-78, there was a reduction in the number of neurons and activation of glial cells in examined regions of the brain. SHD-91 caused severe neurode-generative effects with changes in the brain structure. In contrast, under the action of SHD-85, the number of neurons was higher and with lower activation of glial cells. Conclusion. Studies showed that among the tested compounds SHD-85 possessed moderate neuroprotective activity and reduced gliosis and neuronal loss induced by Corazol. Keywords: anti-seizure drugs, pyrazolylthienopyridines, hippocampus, entorhinal cortex, histopathological examination